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Background: TARGET I randomized controlled trial (RCT) demonstrated that the
novel abluminal groove-ﬁlled biodegradable polymer sirolimus-eluting stent FIRE-
HAWK (MicroPort Medical, Shanghai, China) was non-inferior to the everolimus-
eluting stent with respect to in-stent late loss at 9 months for the treatment of single de
novo coronary lesions. The aim of this study was to evaluate the clinical safety and
effectiveness of FIREHAWK in a large cohort of patients from the TARGET clinical
program.
Methods: An objective performance criterion (OPC) study was required prospectively
by the China Food and Drug Administration for new drug-eluting stent. With the
primary endpoint of target lesion failure (TLF) deﬁned as the composite of cardiac
death, target vessel myocardial infarction, or ischemia-driven target lesion revascu-
larization at 12 months, the pre-speciﬁed objective value of 9% and the expected target
value of 6.5% were chosen, a total of 995 patients would yield 80% power to detect
OPC. Therefore, a patient-level pooled analysis derived from TARGET I RCT
(n¼227), TARGET I long stent cohort (n¼50), and TARGET II registry (n¼730) was
performed in 1007 patients with de novo native coronary lesions. All patients were
exclusively treated with FIREHAWK stent and the follow-up visits are at 1-, 6-, 12-
month, and annually up to 5 years.
Results: The 12-month rate of TLF 3.9% (95%CI [2.8%, 5.3%]), was signiﬁcantly
lower than the pre-speciﬁed objective value (p < 0.0001) and also lower than the
expected rate. The major results are shown in the table.Table. Baseline Characteristics, Procedural Results, and Clinical Outcomes
　 All FIREHAWK patients, n=1007
Age, years 58.7  9.1
Male, % (n) 70.6 (711)
Diabetes Mellitus, % (n) 23.1 (233)
Number of Target Lesion per Patient, n 1.30  0.57
Baseline QCA 　
Reference Vessel Diameter, mm 2.81  0.49
Lesion Length, mm 23.0  12.7
Number of Stents per Patient, n 1.58  0.91
Device Success, % (n/N) 99.9 (1592/1594)
Lesion Success, % (n/N) 99.6 (1309/1314)
Clinical Outcomes at 12 Months 　
Death, % (n) 0.8 (8)
Cardiac Death 0.5 (5)
Myocardial Infarction, % (n) 2.8 (28)
Q Wave MI 0.1 (1)
Non Q Wave MI 2.7 (27)
Target Vessel MI 2.8 (28)
Ischemia-Driven TLR, % (n) 0.9 (9)
TLF, % (n) 3.9 (39)
Deﬁnite / Probable Stent Thrombosis, % (n) 0.1 (1)
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pooled analysis. 12-month clinical data indicates FIREHAWK stent would be
a promising treatment option for patients with de novo coronary lesions. However, an
all-comers RCT is warranted to further conﬁrm its clinical beneﬁts. (ClinicalTrials.gov
Identiﬁer: NCT01196819 and NCT014164)
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Background: Percutaneous intervention (PCI) strategy for long diffuse lesions remains
a challenge. Aiming for complete lesions coverage often result in "full-metal jacket"
(FMJ)", which is dreaded by some operators due to fear of stent thrombosis and
restenosis. On the contrary incomplete lesion coverage is an independent risk factor for
restenosis and possibly stent thrombosis. Understanding the long-term clinical effects
of FMJ is important and we aim to address this from a large cohort of patients.
Methods: Between 2002-2007, 274-patients (297-long diffuse native coronary
lesions) underwent PCI utilizing ﬁrst generation drug-eluting stents (DES). FMJ was
described as lesions requiring 60 mm of continuous stent. The measured end-points
were cardiac death, target vessel myocardial infarction (MI), target lesion vasculari-
zation (TLR), target vessel vascularization (TVR) and major adverse cardiac events
(MACE) deﬁned as composite of cardiac death, MI and TVR.
Results: The mean age of patients were 62.111 years and 257 (94%) were male.
Eighty-two patients (30%) were diabetic. The mean length of stents used was
75.116.4mm (60-150). The lesion was a chronic total occlusion in 33% (n¼98).
IVUS was utilised to optimise stents in 106 (36%) lesions. The median follow-up was
74.7 months (IQR:58-96), (3-year & 5-year follow-ups were achieved in 97% and
93% of patients respectively). Angiographic follow-up was achieved in 62% of
patients. The rates of cardiac death, MI, TLR and TVR were: 5.8% (n¼16), 6.2%
(n¼17), 27.3% (n¼81) and 30% (n¼89) respectively. The MACE rate was 34%,
which was driven mainly by TVR. Stent thrombosis (deﬁnite and probable) occurred
in 10-patients (3.6%). The independent predictors of MACE were diabetes (HR: 1.69;
CI: 1.09-2.59; p¼0.01), smoking (HR: 2.05; CI: 1.34-3.13; p¼0.001) and low EF
(HR: 0.971; CI: 0.97-0.954; p¼0.001).
Conclusions: The long-term follow-up of patients with FMJ is acceptable especially
in regards to hard endpoints. The high MACE rate was driven mainly by TVR, which
is not uncommon given the complexity of lesions treated and may also be related to
high rates of angiographic follow-up. The availability of newer-generation DES may
improve these long-term results.
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Background: The PRO-Kinetic Energy is a thin strut (60mm) cobalt chromium alloy
bare metal stent, which is coated with a thin layer of amorphous silicon carbide. The
aim of this registry is to evaluate its clinical performance in a large patient population
in standard clinical care.
Methods: 1,016 consecutive patients with de-novo and restenotic coronary artery
lesions were enrolled at 48 sites in 10 countries. Primary endpoint was MACE at
6 months. Secondary were MACE at 12 and 24-month, TVR and stent thrombosis at
6, 12, and 24 months. Pre-speciﬁed subgroups were: diabetes, ACS and stent size of
2.75 mm.
Results: Mean age of the patients was 66.112.5 years, the majority of patients
presented with hypertension (72.0%), hyperlipidemia (69.2%), and history of smoking
(62.6%). 16.5% had diabetes, 46.1% acute coronary syndrome and 24.9% were
implanted with a stent size 2.75 cm. Type A, B1, B2 and C lesions were presented in
20.5%, 40.5%. 28.6% and 10.5% of the cases, and 12.8% were bifurcation lesions.
MACE at 12 months is shown in ﬁgure 1. It includes 2.8% cardiac death, 2.0% MI and
4.4% TLR. Deﬁnite stent thrombosis occurred in 0.5% of the patients. Despite
signiﬁcant differences in baseline characteristics, there was no signiﬁcant difference inacts/POSTER/Bare Metal and Drug-Eluting Stent Studies B59
